High Level of Serum Complement C3 Expression is Associated with Postoperative Vasculopathy Progression in Moyamoya Disease

References

• Suzuki J, Takaku A, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288–299. doi:10.1001/archneur.1969.00480090076012
   PubMedGoogle Scholar
• Lin R, Xie Z, Zhang J, et al. Clinical and immunopathological features of Moyamoya disease. PLoS One. 2012;7(4):e36386. doi:10.1371/journal.pone.0036386
   PubMed Web of Science ®Google Scholar
• Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6(7):e22542. doi:10.1371/journal.pone.0022542
   PubMed Web of Science ®Google Scholar
• Okazaki S, Morimoto T, Kamatani Y, et al. Moyamoya disease susceptibility variant RNF213 p.R4810K increases the risk of ischemic stroke attributable to large-artery atherosclerosis. Circulation. 2019;139(2):295–298. doi:10.1161/CIRCULATIONAHA.118.038439
   PubMed Web of Science ®Google Scholar
• Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. New Engl J Med. 2009;360(12):1226–1237. doi:10.1056/NEJMra0804622
   PubMed Web of Science ®Google Scholar
• Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke. 1983;14(1):50–58. doi:10.1161/01.STR.14.1.50
   PubMed Web of Science ®Google Scholar
• Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24(12):1960–1967. doi:10.1161/01.STR.24.12.1960
   PubMed Web of Science ®Google Scholar
• Duan L, Wei L, Tian Y, et al. Novel susceptibility loci for moyamoya disease revealed by a Genome-Wide Association Study. Stroke. 2018;49(1):11–18. doi:10.1161/STROKEAHA.117.017430
   PubMed Web of Science ®Google Scholar
• Kanamori F, Yokoyama K, Ota A, et al. Transcriptome-wide analysis of intracranial artery in patients with moyamoya disease showing upregulation of immune response, and downregulation of oxidative phosphorylation and DNA repair. Neurosurgical Focus. 2021;51(3):E3. doi:10.3171/2021.6.FOCUS20870
   PubMed Web of Science ®Google Scholar
• Otten EG, Werner E, Crespillo-Casado A, et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature. 2021;594(7861):111–116. doi:10.1038/s41586-021-03566-4
   PubMed Web of Science ®Google Scholar
• Ueno M, Oka A, Koeda T, Okamoto R, Takeshita K. Unilateral occlusion of the middle cerebral artery after varicella-zoster virus infection. Brain Dev. 2002;24(2):106–108. doi:10.1016/S0387-7604(02)00005-0
   PubMed Web of Science ®Google Scholar
• Tashiro R, Niizuma K, Kasamatsu J, et al. Dysregulation of Rnf 213 gene contributes to T cell response via antigen uptake, processing, and presentation. J Cell Physiol. 2021;236(11):7554–7564. doi:10.1002/jcp.30396
   PubMed Web of Science ®Google Scholar
• Sigdel TK, Shoemaker LD, Chen R, et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients. Orphanet J Rare Dis. 2013;8(1):45. doi:10.1186/1750-1172-8-45
   PubMedGoogle Scholar
• Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015;14(12):857–877. doi:10.1038/nrd4657
   PubMed Web of Science ®Google Scholar
• Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40(8):560–566. doi:10.1080/08916930701510673
   PubMed Web of Science ®Google Scholar
• Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359–367. doi:10.1038/nrneph.2017.37
   PubMed Web of Science ®Google Scholar
• Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19(8):517–532. doi:10.1038/s41577-019-0160-5
   PubMed Web of Science ®Google Scholar
• Speidl WS, Kastl SP, Huber K, Wojta J. Complement in atherosclerosis: friend or foe? J Thromb Haemost. 2011;9(3):428–440. doi:10.1111/j.1538-7836.2010.04172.x
   PubMed Web of Science ®Google Scholar
• Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol Med. 2022;28(11):939–950. doi:10.1016/j.molmed.2022.08.009
   PubMed Web of Science ®Google Scholar
• Kato M, Kudo Y, Hatase M, et al. Moyamoya Disease Associated with a Deficiency of Complement Component 6. J Stroke Cerebrovasc Dis. 2022;31(8):106601. doi:10.1016/j.jstrokecerebrovasdis.2022.106601
   PubMed Web of Science ®Google Scholar
• Troedson C, Wong M, Dalby-Payne J, et al. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus. 2013;22(6):639–643. doi:10.1177/0961203313486950
   PubMed Web of Science ®Google Scholar
• Fujimura M, Tominaga T, Kuroda S, et al. 2021 Japanese Guidelines for the Management of Moyamoya Disease: guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society. Neurol Med Chir. 2022;62(4):165–170. doi:10.2176/jns-nmc.2021-0382
   PubMed Web of Science ®Google Scholar
• Ahn SH, Lee J, Kim YJ, et al. Isolated MCA disease in patients without significant atherosclerotic risk factors: a high-resolution magnetic resonance imaging study. Stroke. 2015;46(3):697–703. doi:10.1161/STROKEAHA.114.008181
   PubMed Web of Science ®Google Scholar
• Mugikura S, Takahashi S, Higano S, Shirane R, Sakurai Y, Yamada S. Predominant involvement of ipsilateral anterior and posterior circulations in moyamoya disease. Stroke. 2002;33(6):1497–1500. doi:10.1161/01.STR.0000016828.62708.21
   PubMed Web of Science ®Google Scholar
• Matsushima T, Inoue T, Suzuki SO, Fujii K, Fukui M, Hasuo K. Surgical treatment of moyamoya disease in pediatric patients--comparison between the results of indirect and direct revascularization procedures. Neurosurgery. 1992;31(3):401–405. doi:10.1227/00006123-199209000-00003
   PubMed Web of Science ®Google Scholar
• Leong KW, Ding JL. The unexplored roles of human serum IgA. DNA Cell Biol. 2014;33(12):823–829. doi:10.1089/dna.2014.2639
   PubMed Web of Science ®Google Scholar
• Mkaddem SB, Christou I, Rossato E, Berthelot L, Lehuen A, Monteiro RC. IgA, IgA receptors, and their anti-inflammatory properties. Curr Top Microbiol Immunol. 2014;382:221–235. doi:10.1007/978-3-319-07911-0_10
   PubMed Web of Science ®Google Scholar
• Yeon JY, Shin HJ, Kong DS, et al. The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease. Stroke. 2011;42(10):2973–2976. doi:10.1161/STROKEAHA.111.622522
   PubMed Web of Science ®Google Scholar
• Rahimi K, Bidel Z, Nazarzadeh M. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053–1064. doi:10.1016/S0140-6736(21)01921-8
   PubMed Web of Science ®Google Scholar
• Webb AJS, Werring DJ. New insights into cerebrovascular pathophysiology and hypertension. Stroke. 2022;53(4):1054–1064. doi:10.1161/STROKEAHA.121.035850
   PubMed Web of Science ®Google Scholar
• Sreenivasan SA, Suri A, Raheja A, et al. Effect of age, stage, and type of surgical revascularization on clinical and angiographic outcome in moyamoya disease - experience from a case series of 175 revascularization procedures. Neurol India. 2022;70(5):2072–2081. doi:10.4103/0028-3886.359200
   PubMed Web of Science ®Google Scholar
• Geisbrecht BV, Lambris JD, Gros P. Complement component C3: a structural perspective and potential therapeutic implications. Semin Immunopathol. 2022;59:101627. doi:10.1016/j.smim.2022.101627
   Google Scholar
• Ma Y, Liu Y, Zhang Z, Yang GY. Significance of complement system in ischemic stroke: a comprehensive review. Aging Dis. 2019;10(2):429–462. doi:10.14336/AD.2019.0119
   PubMed Web of Science ®Google Scholar
• Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105(25):3025–3031. doi:10.1161/01.CIR.0000019584.04929.83
   PubMed Web of Science ®Google Scholar
• Garcia-Arguinzonis M, Diaz-Riera E, Pena E, et al. Alternative C3 complement system: lipids and atherosclerosis. Int J Mol Sci. 2021;23(1):22. doi:10.3390/ijms23010022
   PubMedGoogle Scholar
• Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR. Moyamoya disease: a summary. Neurosurgical Focus. 2009;26(4):E11. doi:10.3171/2009.1.FOCUS08310
   PubMed Web of Science ®Google Scholar
• Gotz P, Braumandl A, Kubler M, et al. C3 deficiency leads to increased angiogenesis and elevated pro-angiogenic leukocyte recruitment in ischemic muscle tissue. Int J Mol Sci. 2021;22(11):5800. doi:10.3390/ijms22115800
   PubMed Web of Science ®Google Scholar